Sleep Aids Market Assessment, By Product [Mattresses and Pillows, Sleep Laboratory Services, Medication, Others], By Sleep Disorder [Insomnia, Sleep Apnea, Restless Legs Syndrome, Narcolepsy, Sleepwalking, Other Sleep Disorders], By Region, Opportunities

Sleep Aids Market Assessment, By Product [Mattresses and Pillows, Sleep Laboratory Services, Medication, Others], By Sleep Disorder [Insomnia, Sleep Apnea, Restless Legs Syndrome, Narcolepsy, Sleepwalking, Other Sleep Disorders], By Region, Opportunities and Forecast, 2017-2031F

Saudi Arabia gene therapy market is projected to witness a CAGR of 23.59% during the forecast period 2024-2031, growing from USD 88.55 million in 2024 to USD 390.11 million in 2031. The growth of the Saudi Arabia gene therapy market is supported by the growing collaborations between leading hospitals and pharmaceutical companies, increasing efforts of biotech companies to propel the availability of gene therapies in Saudi Arabia, and rising cases of genetic diseases.

The rising efforts by the government to strengthen the country’s healthcare sector and increase the availability of advanced therapeutic solutions are driving the Saudi Arabia gene therapy market growth. The government is increasingly encouraging foreign collaborations to bolster the expansion of the pharmaceutical sector in Saudi Arabia. In June 2022, Novartis AG and Saudi Arabia’s Ministry of Investment (MISA) signed a memorandum of understanding (MoU) for the co-creation of cell and gene centers in Saudi Arabia.

Additionally, the rising research and development activities by various startups in Saudi Arabia are also providing lucrative growth opportunities to the market. In May 2024, NanoPalm Ltd. announced that they are working on developing a biorobot by combining gene therapy, artificial intelligence, and nanotechnology to aid patients with sickle cell disease. The biotech company is dedicated to developing next-generation nanomedicines for accelerated and affordable pharmaceutical research and development activities. NanoPalm aims to leverage its expertise in developing a product that removes the gene responsible for sickle cell disease from the patient’s body. Such efforts are expected to aid the country in combating different genetic diseases and disorders and positively influence the expansion of the Saudi Arabia gene therapy market.

Rising Collaborations to Bolster the Market

The increasing collaborations between leading hospitals and pharmaceutical companies to augment the availability and localization of gene therapies in the country are propelling the Saudi Arabia gene therapy market. In July 2024, Boston Oncology and King Fahd Medical City signed a MoU for localizing cell and gene therapy projects in Saudi Arabia. The MoU aligns with the latter’s goal of transforming the healthcare sector and aims to enhance the provision of healthcare services for patients by ensuring the localization of modern technologies. Under Vision 2030, the Medical City also aims to develop local capabilities for advanced medical technologies and treatments by fostering partnerships and collaborations with international and national institutions and companies. Additionally, the growth of CAR-T cell therapy and rise of ultra-targeted therapies, using genomic data, particularly in oncology are further bolstering collaborations across Saudi Arabia’s healthcare ecosystem.

Increasing Efforts of Biotech Companies Boost Market Expansion

The growing efforts of different biotech companies based in Saudi Arabia to bolster the availability of gene therapies in the country by collaborating with global companies are expected to augment the Saudi Arabia gene therapy market growth. In February 2022, SaudiVax and Merck & Co., Inc. announced that they are working together to provide advanced medicines, including gene therapies to patients in Saudi Arabia. Such partnerships can be attributed to rising unmet requirements of the patient population and increasing emphasis on ensuring the availability of cutting-edge therapeutic solutions in the country. The increasing efforts can also be attributed to the inability of small molecule drugs in replacing, repairing or inhibiting the functions of the mutated genes. The conventional pharma drug development is able to only provide palliative treatments for various diseases and disorders, similar to errors in computer codes that can only be fixed after writing a subroutine that is able to bypass the segment of the code and not by switching out the components.

Hospitals Hold Major Market Share

The growing efforts of the hospitals to augment the availability of gene therapies for patients with chronic and genetic diseases is boosting the growth of the Saudi Arabia gene therapy market. In November 2023, the King Faisal Specialist Hospital and Research Centre (KFSH&RC) successfully administered advanced gene therapy to patients with hemophilia and demonstrated its efficacy in elevating the deficient clotting factor with a single dose, allowing patients to engage in everyday activities without the constant need of preventive medication. Such introductions showcase hospitals' commitment to integrating cutting-edge technologies and leveraging the available resources to improve treatment outcomes, healthcare delivery efficiency, and patient experience.

Additionally, the growing investments of the government towards the upgradation of hospitals in the country is also expected to bolster the availability of novel therapeutic solutions, including gene therapies, across different healthcare institutions, positively influencing the market’s expansion. For instance, in June 2024, the Ministry of Health granted Altakassusi Alliance Medical a public-private partnership for strengthening imaging and radiology services across seven hospitals. They also intend to privatize 2,300 health institutions and 290 hospitals, increasing the participation of the private sector to 65% from 40%.

Genetic Diseases Account for Significant Market Share

The growing threat of genetic diseases in the country is bolstering the Saudi Arabia gene therapy market demand. According to an article published in the Thrombosis Journal in November 2023, beta-thalassemia and sickle cell anemia are 13.6 and 49.6 per 1000 population, respectively, in Saudi Arabia. Thus, this propels the requirement for gene therapies for genetic diseases in the country as various genetic disorders are caused by changes in genes, often affect the different systems of the body, and are incurable. Gene therapies aid healthcare professionals in treating different genetic diseases by altering the genetic makeup of the patient by introducing a non-faulty copy of the gene to take the place of the altered copy responsible for causing the disease or introducing a new gene in cells to battle the disease.

Future Market Scenario (2024-2031F)

As per the Saudi Arabia gene therapy market analysis, the market is expected to witness significant growth opportunities due to rising investments in the biotechnology industry to harness its benefits in the healthcare sector. The country is expected to launch several initiatives to bolster the growth of the biotech industry and is seeking partnerships and collaborations with different market players on various projects, including the Saudi Genome Program, to provide their citizens with a better foundation for tomorrow.

Additionally, the government's increasing investments in enhancing the healthcare sector are also expected to positively influence the expansion of the Saudi Arabia gene therapy market. The country is focusing on developing medical cities to become a global healthcare player. Furthermore, the Saudi Deputy Minister of Investment Transactions expects the healthcare sector to contribute USD 66.6 billion by 2030 to the country’s GDP.

Key Players Landscape and Outlook

The increasing efforts of the market players to bolster the availability of gene therapies in the country are propelling the market’s expansion. In January 2024, the Saudi Arabia Food and Drug Authority (SFDA) approved Casgevy by Vertex Pharmaceuticals Incorporated, the first gene therapy for thalassemia and sickle cell anemia in patients 12 or older. Cell-based gene therapy uses CRISPR/ Cas9 type of genome editing technology and modifies the patient's hematopoietic stem cells with the help of this technology. The SFDA evaluated the safety, quality, and effectiveness of the treatment before approval was granted. Such approvals are expected to aid the country in combating the threat of hereditary blood diseases and provide lucrative growth opportunities to the market.